Materia Medica of New and Old Homeopathic Medicines

243 Pages·2018·5.25 MB·English

David S. Riley
Materia Medica
of New and
Old Homeopathic
Medicines
2nd Edition
Materia Medica of
New and Old Homeopathic Medicines
David S. Riley
Materia Medica
of New and
Old Homeopathic
Medicines
2nd Edition
123
David S. Riley
Portland, OR
ISBN 978-3-662-54191-3 978-3-662-54192-0 (eBook)
https://doi.org/10.1007/978-3-662-54192-0
Library of Congress Control Number: 2017961556
Springer
© Springer-Verlag GmbH Germany 2012, 2018
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole
or part of the material is concerned, specifically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical
way, and transmission or information storage and retrieval, electronic adaptation, computer
software, or by similar or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in
this publication does not imply, even in the absence of a specific statement, that such names
are exempt from the relevant protective laws and regulations and therefore free for general
use.
The publisher, the authors and the editors are safe to assume that the advice and informa-
tion in this book are believed to be true and accurate at the date of publication. Neither the
publisher nor the authors or the editors give a warranty, express or implied, with respect to
the material contained herein or for any errors or omissions that may have been made. The
publisher remains neutral with regard to jurisdictional claims in published maps and insti-
tutional affiliations.
Cover Design: deblik Berlin
Cover illustration: © deblik Berlin
Printed on acid-free paper
This Springer imprint is published by Springer Nature
The registered company is Springer-Verlag GmbH, DE
The registered company address is: Heidelberger Platz 3, 14197 Berlin, Germany
V
Foreword 2nd Edition
One of the unique characteristics of homeopathy as an evidence-based medical
system is the conduct of provings on healthy volunteers. Provings are sometimes
compared to conventional phase 1 clinical trials in which the safety and phar-
macokinetics of new chemical entities are investigated. While the conduct of a
clinical experiment on healthy volunteers as part of the early stage of drug
development is a common factor, from that point onwards, homeopathic drug
provings are a ›drug development pillar‹ unique to homeopathy.
Homeopathic provings were introduced by Hahnemann, and have been con-
ducted for over 200 years. It is fair to say that David Riley has been one of the
most prolific late 20th century modernizers of homeopathic provings, and this
is duly reflected in the 1st edition of his book, which was published in 2012.
During the last 5 to 10 years, we have seen what could be described as a
›21st century revolution‹ in the domain of proving methodology and conduct.
For instance, the Homœopathic Pharmacopœia Convention of the United
States (HPCUS) published its first detailed and extensive proving guideline in
2012. In recent years, the HPCUS proving committee, the European Committee
of Homeopathy (ECH) proving committee and the Liga Medicorum Homœo-
pathica Internationalis (LMHI) proving committee held several joint meetings,
resulting in giant steps forwards towards a global harmonization of proving
guidelines. Much more detailed guidance is now available for all aspects of the
conduct of provings, ranging from personnel qualifications and training,
description of the investigational proving substance, design, data collection and
record keeping, safety assurance, data analysis as well as legal and ethical aspects.
This significantly revised 2nd edition of Riley’s book is therefore particularly
useful, because apart from incorporating many improvements as well as some
additional substances, it also reflects the most recent developments in the
domain of drug provings. This is immediately evident in the first chapter of the
2nd edition by the more contemporary use of language: for instance, explicit
reference is made to the need for Institutional Review Board (IRB) approval of
protocols, as well as the Guideline for Good Clinical Practice (GCP) issued by
The International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use (ICH)1. Also, explicit reference is made to the
regulatory context in that homeopathic provings may be viewed as a special type
of phase 1 clinical trials. The important topic of clearly defining mild and
transient proving symptoms as specific for provings, while acknowledging the
need for adverse event reporting and handling compliant with modern clinical
1 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use (ICH). ICH harmonized tripartite guideline: Guideline for Good Clinical Practice
E6(R1): Current Step 4 version. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Dated 10 June 1996. Accessed July 06, 2017.
VI Foreword 2nd Edition
research standards, is mentioned from the onset. This effectively sets the tone
for this 2nd edition: while provings are specific and unique to homeopathy, at
the same time, provings are experiments on human subjects which need to be
embedded within the regulatory and legal framework of modern, evidence-
based medicine.
The layout of the book has been improved further, and some change made in the
way how the remedy pictures are reported. Notably, ›dream‹ symptoms are now
listed under a separate header instead of being included in the ›mind‹ sections,
and the ›generalities‹ now appear at the end of each chapter.
With regard to the listing and indexing of the provings, all substance names have
now been consistently latinized. These are followed by the commonly used
synonyms. As a useful new feature, the synonyms are also listed in Appendix 2
›Register of synonyms‹ at the end of the book, enabling easy identification of the
appropriate Latin names.
In terms of content, 7 substances have been added: 2 provings conducted in the
1990s (Acidum fumaricum and Manganum phosphoricum), as well as 5 more
recent provings conducted between 2002 and 2011 (para-Benzochinonum,
Pelargonium sidoides, Levothyroxinum, Magnesium gluconicum, Magnesium
oroticum).
Apart from these new provings, the materia medica of 12 provings published
in the 1st edition have been updated and extended (Acidum cis-aconiticum,
Adenosinum triphosphoricum dinatrium (ATP), Anthrachinonum, Arteria
suis, Baryta oxalsuccinicum, Embryo suis, Glandula suprarenalis suis, Hydro-
chinonum, Mucosa nasalis suis, Naphthochinonum, Placenta suis, T richinoylum).
The significant advances in proving conduct and methods made during the last
5–10 years include improvements in the methods for ›symptom extraction‹
based on the ›raw data‹ in the prover diaries. Reassessing and reworking the
original diary data has enabled the extraction of a ›sharper‹ symptom picture for
these substances. So, whilst the overall ›remedy picture‹ of these substances
has remained the same, the ›resolution‹ has increased significantly. This is an
important advance because the successful individualization of prescribing in
homeo pathy hinges on matching the symptom picture of the patient with the
›remedy picture‹ of the homeopathic substance.
While some homeopaths argue that there are enough substances already available
in the homeopathic materia medica, I am firmly convinced that the success of
homeopathy will be determined by its continuing innovation, which includes the
introduction of new substances in the materia medica. New substances will hope-
fully prove to be clinically useful for both existing and new medical c hallenges we
are facing in this day and age. Riley’s book is therefore an example of how we can
pave the way for homeopathy’s continued and increased success in the future.
Dr. Robbert van Haselen
Member Proving Working Group of the Pharmacopoeia Review Committee
(PRC) of the Homœopathic Pharmacopœia of the United States (HPUS)
VII
About the Author
David S. Riley MD
5 Editor of The Permanente Journal as well as the Integrative
Medicine: A Clinician’s Journal
5 Co-Founder, Integrative Medicine Institute, Portland/USA
5 Adjunct Professor, Helfgott Research Institute at the
National University of Natural Medicine (NUNM),
Portland/USA
IX
Table of Contents
1 Homeopathic Drug Provings . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 Acidum alpha-ketoglutaricum . . . . . . . . . . . . . . . . . . . . . . . . 5
3 Acidum alpha-lipoicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
4 Acidum cis-aconiticum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
5 Acidum citricum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
6 Acidum fumaricum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
7 Acidum oroticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
8 Acidum succinicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
9 Adenosinum mono hydrogen phosphoricum (cAMP) .. . . . . . . 31
10 Adenosinum trip hosphoricum dinatrium (ATP) .. . . . . . . . . . . 35
11 Agnus castus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
12 Anthrachinonum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
13 Arteria suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
14 Ascophyllum nodosum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
15 Bacterium coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
16 Baryta oxalsuccinicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
17 Benzochinonum, para- .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
18 Bryonia alba . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
19 Bryonia dioica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
20 Calendula officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
21 Cardiospermum halicacabum .. . . . . . . . . . . . . . . . . . . . . . . . 73
22 Cartilago suis .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
23 Caulophyllum thalictroides . . . . . . . . . . . . . . . . . . . . . . . . . . 81
24 Coenzymum A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
25 Colocynthis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
26 Cuprum formicicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
27 Cysteinum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
28 Embryo suis .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
29 Fucus vesiculosus .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
30 Fumaria officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
31 Funiculus umbilicalis suis .. . . . . . . . . . . . . . . . . . . . . . . . . . . 111
32 Galphimia glauca .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
33 Geranium robertianum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
34 Glandula suprarenalis suis . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
35 Glyoxalum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
36 Hepar suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
37 Hydrochinonum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
38 Kalium tetraiodobismutatum .. . . . . . . . . . . . . . . . . . . . . . . . 137
39 Levothyroxinum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
40 Luffa operculata . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
41 Magnesium gluconicum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
42 Magnesium oroticum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
X Table of Contents
43 Mahonia aquifolium .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
44 Manganum phosphoricum .. . . . . . . . . . . . . . . . . . . . . . . . . . 155
45 Medulla ossis suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
46 Methylglyoxalum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
47 Mucosa nasalis suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
48 Myosotis arvensis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
49 Nadidum (NADH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
50 Naphthochinonum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
51 Natrium oxalaceticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
52 Natrium pyruvicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
53 Nicotinamidum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
54 Okoubaka aubrevillei .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
55 Oleander . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
56 Oleum Pini .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
57 Oxalis acetosella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
58 Pancreas suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
59 Pelargonium sidoides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
60 Placenta suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
61 Pyridoxinum hydrochloricum .. . . . . . . . . . . . . . . . . . . . . . . . 209
62 Riboflavinum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
63 Sinusitisinum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
64 Staphylococcus nosode . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
65 Streptococcus nosode . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
66 Symphytum officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
67 Terebinthina laricina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
68 Thiaminum hydrochloricum .. . . . . . . . . . . . . . . . . . . . . . . . . 235
69 Tormentilla . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
70 Trichinoylum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
71 Urtica urens .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
72 Veronica officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
73 Zincum aceticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255
74 Zincum gluconatum .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259
75 References .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263
Appendices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265
Appendix 1: Overview of Provings.. . . . . . . . . . . . . . . . . . . . . . . . . 266
Appendix 2: Register of Synonyms . . . . . . . . . . . . . . . . . . . . . . . . . 276
1
1
Homeopathic Drug
P rovings
General Methodological Considerations
Homeopathic drug provings (HPDs) are a clinical research tool unique to homeopathy that
provides qualitative information on the use of homeopathic medications in healthy people
and guides prescribing for patients. In turn, the use of homeopathic medications in clinical
practice by experienced clinicians further refines the symptom picture. The HDP results
presented in this Materia Medica were conducted from 1993‒2011 using Institutional Review
Boards (IRBs) or Ethics Commissions (ECs) approved protocols, explicitly following Good
Clinical Practice (GCP) guidelines, as well as pre-determined criteria for adverse events and
the selection of symptoms (Riley 1997).
Since the early 1800s HDPs have been used to evaluate the effects of homeopathic substances
using a similar clinical trial design to Phase I trials. Regulatory agencies that oversee Phase I
trials define adverse events as untoward medical occurrences in clinical trial subjects while
administered a pharmaceutical product. Subjects in HPDs experience a range of mild, tem-
porary symptoms that are a key component in establishing a symptom picture for a homeo-
pathic medication. The quality and range of symptoms are usually not known prior to the
HPD. Protocols for HPDs need to include criteria for handling adverse events in an HDP.
Symptoms experienced by subjects in a HDP are organized into a pattern to facilitate the
clinical use of the homeopathic medication. Dr Samuel Hahnemann, the founder of homeo-
pathy, was a physician, chemist and translator of scientific literature. He conducted a now
famous self-experiment with cinchona bark, observing symptoms of intermittent fever
associated with malaria. This self-experiment was a foundation for his recommendations for
HDPs outlined in his seminal work The Organon of the Art of Healing (Hahnemann 1983). In
the Organon, Hahnemann emphasized that, in his opinion, a HDP was essential in deter-
mining the effects of a substance on the human being: »[…] There is no other possible way of
correctly ascertaining the characteristic action of medicines on human health – no single surer,
more natural way – than administering individual medicines experimentally to healthy people
in moderate doses in order to ascertain what changes, symptoms, and effects each in particular
brings about in the body and the psyche . […]« [§108]. As can be noted in §108, he stressed the
need to conduct HDPs using healthy volunteers as the best method for achieving an accurate
homeopathic symptom picture. The Organon provides scientific directions on how to conduct
a HDP [§§105–145].
© Springer-Verlag GmbH Germany 2018
D.S. Riley, Materia Medica of New and Old Homeopathic Medicines
DOI 10.1007/978-3-662-54192-0_1